| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6933395 | BAYER HLTHCARE | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
Aug, 2017
(6 years ago) | |
| US8906890 | BAYER HLTHCARE | Very low-dosed solid oral dosage forms for HRT |
Oct, 2031
(7 years from now) | |
Angeliq is owned by Bayer Hlthcare.
Angeliq contains Drospirenone; Estradiol.
Angeliq has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Angeliq are:
- US6933395
Angeliq was authorised for market use on 29 February, 2012.
Angeliq is available in tablet;oral dosage forms.
The generics of Angeliq are possible to be released after 22 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Mar 01, 2015 |
Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient
Market Authorisation Date: 29 February, 2012
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage
ANGELIQ family patents
